language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
PENPEN

$351.393

+37.96
arrow_drop_up12.11%
Current Market·update15 Jan 2026 17:47
Day's Range
346.21-352.15
52-week Range
221.26-352.15

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-05
Next Earnings TimeAfter Market Close
Volume6.12M
Average Volume 30d504.9K

AI PEN Summary

Powered by LiveAI
💰
213.13
Valuation (P/E Ratio)
High P/E suggests growth expectations or potential overvaluation.
📈
0.152
EPS Growth (YoY)
Strong earnings growth reported in recent quarters.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
74

Penumbra exhibits strong fundamentals with consistent revenue and EPS growth, coupled with a healthy balance sheet. Thematic tailwinds in medical devices and neurotechnology are positive, but current valuation metrics and mixed technical signals warrant a 'Buy' rating with a cautious approach.

Strong

Thematic

78

Penumbra is well-positioned within the growing medical device market, particularly in neurovascular and peripheral vascular intervention. Advancements in medical technology and an aging global population provide strong secular tailwinds.

Strong

Fundamental

80

Penumbra demonstrates robust revenue and EPS growth, with improving profitability and a solid balance sheet. While valuation multiples appear high, the company's financial health and growth trajectory support a positive fundamental outlook.

Neutral

Technical

60

The stock is trading below its 52-week high and recent moving averages, indicating some short-term weakness. While oscillators suggest potential for a bounce, the overall trend appears to be consolidating or slightly bearish in the short term.

FactorScore
Medical Device Innovation85
Healthcare Spending Trends80
Competitive Landscape70
Regulatory Environment75
Demographic Shifts85
FactorScore
Valuation45
Profitability70
Growth85
Balance Sheet Health85
Cash Flow75
Earnings Consistency85
FactorScore
Trend Analysis40
Momentum65
Volume Confirmation70
Support & Resistance65
Short-term Oscillators70

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (6)

Valuation chevron_right

Positive Earnings Surprise History

Penumbra (PEN) has a history of positive EPS surprises, with the last four quarters showing actual EPS exceeding estimates by an average of 34.5%. This suggests strong operational execution and potentially underestimated future performance.

Financial Health & Liquidity chevron_right

Strong Cash Position

As of Q4 2024, Penumbra has $324.40 million in cash equivalents, significantly exceeding its total liabilities of $382.25 million when considering current liabilities. The company has maintained positive free cash flow in recent annual periods, indicating good cash generation capabilities.

Show More 🔒
thumb_down

Bearish Points (8)

Valuation Risk chevron_right

High Trailing P/E Ratio

The trailing P/E ratio is 213.13 (TTM), and for the latest reported year (2024), it's 656.3. These are exceptionally high multiples, suggesting that the company's current earnings do not justify its market valuation without significant future growth.

Growth Deceleration chevron_right

Negative Net Income in Recent Quarter

Penumbra reported a net loss of -$6.02 million in Q2 2024, with a net margin of -20.1%. This is a significant deterioration from previous quarters and raises concerns about short-term profitability.

Show More 🔒

Calendar

July 2025

30

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.90

A: $0.82

L: $0.71

H: 330.00M

A: 327.37M

L: 325.50M

Profile

Employees (FY)4.5K
ISINUS70975L1070
FIGI-

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Seasonals

2025
2024
2023
2022
2021

Price Target

311.94 USD

The 39 analysts offering 1 year price forecasts for PEN have a max estimate of 340.00 and a min estimate of 260.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
37.6M (97.01%)
Closely held shares
1.16M (2.99%)
38.7M
Free Float shares
37.6M (97.01%)
Closely held shares
1.16M (2.99%)

Capital Structure

Market cap
8.91B
Debt
223.39M
Minority interest
0.00
Cash & equivalents
324.4M
Enterprise value
8.81B

Valuation - Summary

Market Cap
8.91B
Net income
102M(1.15%)
Revenue
941M(10.55%)
8.91B
Market Cap
8.91B
Net income
102M(1.15%)
Revenue
941M(10.55%)
Price to earning ratio (P/E)87.00x
Price to sales ratio (P/S)9.50x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
1.19B
COGS
439.62M
Gross Profit
755M
OpEx
668.77M
Operating Income
86.22M
Other & Taxes
72.21M
Net Income
14.01M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒